Citius Oncology, Inc. (NASDAQ:CTOR) saw its stock rise 4.1% after announcing a new distribution services agreement with Cencora to broaden the reach of its FDA-approved immunotherapy, LYMPHIR.
The deal with Cencora—formerly AmerisourceBergen (NYSE:COR)—will extend the wholesale distribution of LYMPHIR (denileukin diftitox-cxdl) through Cencora’s extensive specialty distribution network. LYMPHIR gained FDA approval in August 2024 for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma.
This agreement builds on an earlier distribution partnership, reinforcing the company’s efforts to efficiently deliver LYMPHIR to healthcare providers nationwide.
“Our agreement with Cencora adds further depth to our distribution strategy and strengthens our ability to deliver LYMPHIR to treatment centers across the country,” stated Leonard Mazur, Chairman and CEO of Citius Oncology and its parent company, Citius Pharmaceuticals.
LYMPHIR is approved for patients with Stage I-III cutaneous T-cell lymphoma who have undergone at least one prior systemic therapy. The treatment is a recombinant fusion protein combining the IL-2 receptor binding domain with diphtheria toxin fragments.
Citius Oncology estimates the initial market opportunity for LYMPHIR to be more than $400 million. The company operates as a majority-owned subsidiary of Citius Pharmaceuticals, Inc. (NASDAQ:CTXR), which holds a 92% stake.
Notably, LYMPHIR carries a boxed warning for capillary leak syndrome, a potentially life-threatening condition. Common side effects include elevated liver enzymes, low albumin, nausea, swelling, anemia, fatigue, and musculoskeletal discomfort.
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.